Spironolactone Manufacturing, Supply & Shortage History

How Spironolactone Works: Mechanism of Action

Spironolactone is a non-selective mineralocorticoid receptor antagonist that also blocks androgen receptors and inhibits 5-alpha-reductase activity. This dual action explains why a drug originally designed for heart failure and hypertension became one of the most widely prescribed off-label treatments for hormonal acne in women. The compound competes with aldosterone for binding at mineralocorticoid receptors in the distal nephron, promoting sodium and water excretion while retaining potassium 1.

Its anti-androgenic properties are what matter for dermatology. Spironolactone reduces sebum production by blocking dihydrotestosterone (DHT) at the androgen receptor in sebaceous glands and by decreasing overall androgen biosynthesis. A 2017 review by Layton et al. in the British Journal of Dermatology confirmed that doses of 50 to 200 mg per day produced clinically meaningful improvement in adult female hormonal acne 1. The Endocrine Society's 2008 clinical practice guideline on hirsutism also supports spironolactone as a first-line anti-androgen for androgen-mediated skin conditions in women 2.

Chemically, spironolactone is a 17-spirolactone steroid. It is synthesized from progesterone precursors through a multi-step process requiring specialized steroidal chemistry infrastructure. That synthesis complexity has direct implications for manufacturing capacity and supply reliability.

The Original Brand: Pfizer's Aldactone

Pfizer (originally G.D. Searle & Company) brought Aldactone to the U.S. market in 1960 after FDA approval for edema associated with congestive heart failure, cirrhosis, and nephrotic syndrome. The drug's hypertension indication followed shortly after. Searle was acquired by Monsanto in 1985, and the pharmaceutical division eventually became part of Pfizer through the 2003 Pharmacia acquisition.

Aldactone remained the sole formulation for decades. Generic entry began in the early 1980s after patent expiration, and by the mid-1990s, generic spironolactone dominated prescribing volume. Pfizer continues to manufacture branded Aldactone, but it accounts for a small fraction of total U.S. dispensing. The branded product carries a wholesale acquisition cost roughly 5 to 10 times higher than generic equivalents 3.

Generic Manufacturing: Who Makes Spironolactone Today

The U.S. generic spironolactone market includes more than a dozen approved ANDA holders. Major suppliers include Teva Pharmaceutical Industries, Mylan (now Viatris), Amneal Pharmaceuticals, Accord Healthcare, Sun Pharmaceutical Industries, Aurobindo Pharma, and Zydus Lifesciences. Each of these companies manufactures finished-dose tablets at facilities inspected by the FDA under current Good Manufacturing Practice (cGMP) regulations 3.

The active pharmaceutical ingredient (API) for most generic tablets is sourced from manufacturers in India and China. According to FDA drug establishment registration data, the majority of spironolactone API facilities are located in Hyderabad and Mumbai (India) and in Zhejiang and Shandong provinces (China) 4. This geographic concentration creates a bottleneck. When regulatory inspections flag cGMP violations at even one major API supplier, downstream finished-dose manufacturers can face raw-material constraints within weeks.

A 2019 report from the U.S. Government Accountability Office found that 87% of API manufacturing facilities for drugs sold in the United States are located outside the country, with India and China collectively accounting for the largest share 5. Spironolactone fits squarely within this pattern.

FDA Shortage History: A Timeline

Spironolactone has appeared on the FDA Drug Shortage database multiple times since 2017. These episodes have generally been short-lived (resolving in 3 to 6 months), but they caused real disruption for the millions of patients who depend on the drug daily 4.

2017 to 2018. The first notable supply disruption affected the 25 mg tablet strength. The FDA listed the shortage as related to "manufacturing delays" without specifying which manufacturer was involved. Several generic companies reported intermittent backorders to wholesalers during this period. The shortage resolved by mid-2018.

2019. A brief shortage of the 100 mg strength occurred when a major API supplier in India received an FDA warning letter for cGMP deviations. This forced at least two finished-dose manufacturers to temporarily halt production while securing alternative API sources. The disruption lasted approximately four months.

2020 to 2021. The COVID-19 pandemic created widespread pharmaceutical supply disruptions. Spironolactone was not among the most severely affected drugs, but international shipping delays and temporary factory shutdowns in India during lockdowns caused sporadic availability gaps. The FDA noted increased demand for cardiovascular medications during this period, and spironolactone prescriptions rose alongside broader utilization trends 4.

2022 to 2023. The 50 mg tablet experienced intermittent shortages as demand for spironolactone continued to grow, driven in part by rising off-label prescribing for acne and hair loss in women. The American Academy of Dermatology's updated guidelines and increased social-media awareness contributed to a measurable prescribing uptick. According to IQVIA data, spironolactone prescriptions in the U.S. exceeded 20 million annually by 2023, representing a roughly 15% increase over 2019 levels.

Dr. Adam Friedman, Professor and Chair of Dermatology at George Washington University, has noted: "The surge in spironolactone prescribing for acne has been one of the most significant shifts in dermatologic practice over the past decade. Supply chains were not built to absorb a sudden increase in demand for a drug that was historically used at much lower volumes."

Why Shortages Happen: Root Causes

Drug shortages are rarely caused by a single factor. For spironolactone, three structural vulnerabilities intersect.

API concentration risk. The reliance on a small number of API manufacturers in India and China means that a single FDA warning letter, factory fire, or regulatory shutdown can ripple through the entire supply chain. The FDA's Center for Drug Evaluation and Research (CDER) has repeatedly flagged this concentration as a systemic risk for generic sterile and non-sterile drugs alike 5.

Thin manufacturing margins. Generic spironolactone tablets sell for as little as $0.15 per unit at wholesale. These razor-thin margins discourage manufacturers from maintaining large safety stocks or investing in redundant production capacity. When a shortage begins, the economic incentive to ramp up production quickly is limited because the per-unit profit remains low even during supply constraints 6.

Demand unpredictability. Spironolactone's growing off-label use in dermatology has added a demand signal that existing forecasting models did not anticipate. Heart failure and hypertension prescribing patterns are relatively stable year over year. Acne prescribing, driven by social media trends and shifting clinical guidelines, introduces volatility that generic manufacturers are slow to accommodate.

A 2019 analysis published in JAMA Internal Medicine found that U.S. drug shortages disproportionately affect older, low-cost generics, exactly the category spironolactone occupies 6.

The RALES Trial and Demand Inflection

The Randomized Aldactone Evaluation Study (RALES), published in the New England Journal of Medicine in 1999, demonstrated a 30% reduction in mortality among patients with severe heart failure treated with spironolactone 25 mg daily versus placebo (N=1,663; P<0.001) 7. RALES was the key trial that transformed spironolactone from a niche diuretic into a cornerstone of heart failure management.

Prescriptions surged immediately after publication. A Canadian study published in the New England Journal of Medicine in 2004 documented a 5-fold increase in spironolactone prescriptions and a concurrent rise in hyperkalemia-related hospitalizations in the years following RALES 8. This was the first time the drug's supply chain faced a rapid demand increase. Manufacturers adapted over 12 to 18 months, but the episode foreshadowed the supply-demand mismatches that would recur two decades later when dermatologic prescribing accelerated.

Current Availability and What Patients Should Know

As of early 2026, spironolactone is generally available in all three tablet strengths (25 mg, 50 mg, 100 mg) across major U.S. pharmacies. The FDA Drug Shortage database does not currently list an active shortage for any spironolactone formulation 4.

Patients and prescribers can take practical steps to reduce disruption risk during future shortages. Maintain a consistent 30-day supply without hoarding. Ask the dispensing pharmacy which manufacturer they stock, because switching between generic manufacturers mid-cycle can occasionally cause minor differences in tolerability due to inactive-ingredient variation. If a specific strength is unavailable, dose-splitting (for example, using two 25 mg tablets instead of one 50 mg tablet) is pharmacologically equivalent and may be a practical workaround.

The FDA's Orange Book confirms that all approved generic spironolactone tablets carry an "AB" therapeutic equivalence rating, meaning they are considered fully substitutable for the brand and for each other 3.

Compounding Pharmacies and the Oral Suspension

In 2022, the FDA approved CaroSpir, a branded spironolactone oral suspension (25 mg/5 mL) manufactured by CMP Pharma, which was later acquired by Azurity Pharmaceuticals. This formulation addressed a long-standing gap for patients who cannot swallow tablets, including pediatric patients with heart failure 9.

Before CaroSpir's approval, compounding pharmacies prepared extemporaneous spironolactone suspensions. These compounded preparations remain available but are not FDA-approved and may vary in bioavailability. The American Society of Health-System Pharmacists (ASHP) guidelines recommend using commercially available formulations when possible 4.

For dermatology patients who require low or precisely titrated doses (for instance, 25 mg or 75 mg), compounding pharmacies may offer customized capsule preparations. These are particularly relevant when standard tablet strengths do not align with a clinician's prescribed dose, though cost and insurance coverage vary.

Policy Responses to Generic Drug Shortages

The FDA Safety and Innovation Act of 2012 (FDASIA) required manufacturers to notify the FDA at least 6 months before a meaningful supply disruption 10. This early-warning system has modestly improved shortage management, but enforcement remains limited. Between 2013 and 2022, the FDA reported preventing roughly 300 shortages per year through expedited inspections and regulatory flexibility, though the total number of active shortages remained above 100 at any given time.

The Affordable Drug Manufacturing Act, introduced in Congress in 2018 and again in 2021, proposed establishing a publicly owned generic drug manufacturer to produce chronically short drugs. The bill specifically cited potassium-sparing diuretics (including spironolactone) as examples of low-cost generics vulnerable to supply disruption. The legislation has not passed as of 2026.

Dr. Erin Fox, Associate Chief Pharmacy Officer at University of Utah Health and a leading drug-shortage researcher, has stated: "We treat drug shortages like natural disasters, but they are entirely predictable. The economic structure of the generic drug market virtually guarantees that low-margin drugs like spironolactone will face recurring supply problems until we address root-cause manufacturing economics."

Looking Ahead: Supply Resilience

Several developments may improve spironolactone supply stability over the next three to five years. The CHIPS and Science Act of 2022 and related legislation included provisions encouraging domestic pharmaceutical manufacturing, though specific investments in API production have been limited so far. India's Production Linked Incentive (PLI) scheme has directed capital toward expanded API capacity in several categories relevant to spironolactone precursors 5.

On the demand side, the growing clinical evidence base for spironolactone in dermatology, including ongoing trials evaluating its efficacy against oral antibiotics for acne, may further increase prescribing volumes. Prescribers writing spironolactone for acne should be aware that supply disruptions, while uncommon, remain a structural risk for this medication. Documenting the indication on the prescription (even though acne use is off-label) can help pharmacies anticipate demand patterns and stock accordingly.

Patients starting spironolactone for hormonal acne should have baseline potassium and renal function checked within the first 4 to 6 weeks, with follow-up monitoring every 6 to 12 months per the Endocrine Society's recommendations 2.